Ruthenium-Mediated (18)F-Fluorination and Preclinical Evaluation of a New CB(1) Receptor Imaging Agent [(18)F]FPATPP

[Image: see text] Cannabinoid receptor 1 (CB1R) controls various physiological and pathological conditions, including memory, motivation, and inflammation, and is thus an interesting target for positron emission tomography (PET). Herein, we report a ruthenium-mediated radiolabeling synthesis and pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Lahdenpohja, Salla, Rajala, Noora A., Helin, Jatta S., Haaparanta-Solin, Merja, Solin, Olof, López-Picón, Francisco R., Kirjavainen, Anna K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497626/
https://www.ncbi.nlm.nih.gov/pubmed/32479723
http://dx.doi.org/10.1021/acschemneuro.0c00313
Descripción
Sumario:[Image: see text] Cannabinoid receptor 1 (CB1R) controls various physiological and pathological conditions, including memory, motivation, and inflammation, and is thus an interesting target for positron emission tomography (PET). Herein, we report a ruthenium-mediated radiolabeling synthesis and preclinical evaluation of a new CB1R specific radiotracer, [(18)F]FPATPP. [(18)F]FPATPP was produced with 16.7 ± 5.7% decay-corrected radiochemical yield and >95 GBq/μmol molar activity. The tracer showed high stability, low defluorination, and high specific binding to CB1Rs in mouse brain.

Ejemplares similares